17^th World Congress on Biomarkers, Cancer Therapy & Clinical Research September 23-24, 2022 Vancouver, Canada

Conference Series LLC Ltd cordially invites all the participants across the globe to attend the “17^th World Congress on Biomarkers, Cancer Therapy & Clinical Research” during September 23-24, 2022 at Vancouver, Canada.

Biomarker 2022 congress will enable to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis. The past six conference series of biomarkers meeting have grounded the best possible researchers in the field of biomarkers from diverse scientific disciplines, and so will be the upcoming.

Biomarkers are important for streamlining drug discovery and development. In addition, biomarkers can be widely used as a tool for disease diagnosis, personalized medication in clinical research. Study design and statistical analysis for biomarker research incorporates various tools from bioinformatics. It further involves patient segmentation and stratification by successful integration of diagnostic tools and clinical data annotation inclusive of classification distribution metrics and pattern recognition. The global market for biomarkers in data statistics is estimated at about $2.4 billion in 2011 and further projected to reach $7.6 billion by 2017 registering a CAGR of 18.3% during the period 2007-2017. The organizations involved are Affymetrix, Agilent Technologies, Biomax Informatics, Illumina, Qiagen etc amongst others across the globe.

Conference Series LLC Ltd organizes 3000+ Global events in conference series every year across  the globe with support from 1000+ more scientific societies and Publishes 700 Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With individuals around the globe concentrated on finding out about Biomarkers, Cancer Therapy and Clinical Research; this is your best chance to achieve the biggest gathering of members from the Biomarkers and Clinical Research people group. Direct presentations, circulate data, meet with present and potential researchers, make a sprinkle with cutting edge medicines, and get name acknowledgment at this 3-day occasion. Widely acclaimed speakers, the latest procedures, advancements and the most current upgrades in Biomarkers, Cancer Theraphy and Clinical Research are the signs of this gathering.

Target Audience:

• Biomarkers and Clinical Research Scientists, Students
• Biomarkers, Cancer Therapy and Clinical Researchers
• Medical Colleges
• Psychiatrists
• Biomarkers and Clinical Research Associations and Societies
• Business Entrepreneurs
• Software developing companies
• Manufacturing Medical Devices Companies
• Cancer Researchers
• Data Management Companies
• Pharmaceutical Companies
• Diagnostics

Biomarkers 2022 will mainly focus on the types of biomarkers, Functional genomics and cytogenetic biomarkers and its clinical research and development, omics technologies  in discovery and its validation, biomarkers of exposure response and susceptibility, biomarkers disorders, techniques to maximize biomarker identification, biomarkers nano science.

Conference Series LLC Ltd, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.Biomarkers 2016 is the world’s largest multidisciplinary cancer meeting. Biomarkers and cancer conferences include scientific keynote lectures, symposia, workshops, exhibitions with the support from Oncology Society and American Oncology Society. Cancer conferences include European oncology conferences, surgical oncology global cancer conference and cancer conferences. 

Track 1: Biomarkers

Biomarker is a characteristic diagnostic tool that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers can be molecules, or genes, gene products, enzymes, or hormones referred as protein biomarkers, analytical biomarkers, blood biomarkers, fluorescent biomarkers, circulating biomarkers and molecular biomarkers to quantify the degree of disease condition. Biomarkers are the measures used to perform a clinical assessment in case of cancer biomarkers. They predict health states in individuals across populations so that appropriate therapeutic intervention can be planned. In the current scenario more than a thousand organizations and universities have contributed to the field of Biomarkers research especially molecular and cancer biomarkers, with its wings spreading across major organizations in USA, UK, Germany and China. The global biomarkers market is expected to grow from $29.3 billion in 2013 to $113.6 billion in 2022, a compound annual growth rate (CAGR) of 12.8%.Different types of biomarkers include Protein biomarkers, Fluorescent biomarkers, Blood biomarkers, Cancer biomarkers, Analytical biomarkers and Molecular Biomarkers.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 2: Cancer Biomarkers

Cancer biomarkers are used to detect the natural course of a tumour and are used to assess chances of developing cancer. Biomarkers in cancer screening play an important role in cancer detection and risk assessment to reduce cancer deaths. Tumour biomarkers are used to detect cancer development and progression. Uterine cervical cancer, endometrial cancer, trophoblastic neoplasms and ovarian cancer are gynaecologic malignancies for which tumour markers are in clinical use. Effective cancer biomarkers are used to reduce cancer mortality rates by facilitating diagnosis of cancers at early stages. Cancer biomarkers can also be used in diagnosis, risk assessment and recurrence of cancer.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 3: Functional Genomics and Cytogenetic Biomarkers

The branch of genomics that determines the biological function and complex association of the genes and their products depicts the functional genomics. The measurable degree of these parameters through various processes and equipment inclusive of Next generation sequencing, Personalized genome sequencing and mi-RNA sequencing utilizing cellular entities to predict SNP biomarkers, immuno fluorescent biomarkers, oxidative stress biomarkers, si-RNA and mi-RNA will aid in better understanding of the disease outcome. The cytogenetic biomarkers are a feasible diagnostic tool to detect DNA and chromatin damage.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 4: Functional Transcriptomics and Profiling Techniques

The newly emerged discipline in the field of cytogenetic and functional genomics is Molecular imaging biomarkers, aids in better visualization of the cellular function and the follow-up of the molecular process in living organisms without penetrance. Roche Diagnostics, GlaxoSmithKline, Siemens Healthcare, GE Healthcare and Merck & Co are a few of the key players in this market as observed in biomarkers congress. The functional genomics and cytogenetic market is estimated to reach 150M$ by 2017.Functional genomics covers various areas of biomarkers applications like Next gen sequencing, Personalized genome sequencing, Micro RNA sequencing and SNP biomarkers. Cytogenetic biomarkers include Immuno flouscent biomarkers, Molecular imaging biomarkers, Oxidative Stress Biomarkers and si-RNA and mi-RNA.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 5: Biomarkers in Clinical Research and Development

The Biomarkers finds its valuable application in the field of Clinical research and development by case study and data management as evident through Biomarker conferences. The Bioethics and intellectual property right establishes the norms and standard of conduct of hypothesis with respect to clinical validation of biomarkers. The incorporation of biomarker in clinical trials for various disease conditions will put forth a valid diagnostic and therapeutic approach utilizing even the medical devices to detect clinical biomarkers. Currently this is the booming industry. Most of the reputed organizations like Pfizer, Parexel and Quintiles are into clinical research and development. The companies, hospitals and clinical research organizations are the hot spots for conducting clinical research with its growth rate increasing exponentially by an estimated  75B$ by 2016.In clinical research and development, clinical biomarkers are used in case study and data management, clinical trials and in medical devices.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 6: Omics Technologies in Biomarkers Discovery and Validation

Biomarkers play a critical role in disease diagnosis and treatment, especially for the early detection of cancer, to enable screening of asymptomatic populations. Recent omics technologies, such as Transcriptomics, genomics and proteomics approaches besides Metabolomics are accelerating the rate of biomarker discovery. The incorporation of techniques like microarray data analysis, computational biology, data mining methods, Transcriptomics and profiling techniques are playing a crucial role in the validation of biomarkers. Since the Human Genome Project was completed in April 2003, genome-wide association studies (GWAS) have contributed toward a greater understanding of the genetic basis of complex diseases and advances in high-throughput technologies. This has enabled researchers to rapidly map the genome of vertebrates, invertebrates and pathogens through cost-effective methods. The applications of Bioinformatics tool in biomarker research is the current emerging field promoting better diagnosable parameters. The global omics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a compound annual growth rate (CAGR) of 18.7%. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally. There are several approaches in biomarkers discovery and validation like genomics and proteomic approaches, Microarray data analysis, Data mining methods and Transcriptomics and profiling techniques by making use of Computational biology and Application of Bioinformatics in biomarker discovery.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 7: Biomarkers of Exposure Response and Susceptibility

Biomarkers of exposure are important in toxicology, because they are an indicator of internal exposure and genetic susceptibility to drug, chemicals or the amount of chemical exposure that got accumulated in the body. Significant advances have been made in developing analytical methods that detect and quantify many natural or synthetic toxins or their breakdown products in the biological matrix. The ability to accurately measure biomarkers of exposure depends upon an adequate understanding of the chemistry and toxicology of the substance under consideration. Epigenetic biomarkers also quantify the degree of exposure to toxic dynamic and pharmacodynamics parameters in pathological and biochemical changes occurring due to exposure to harmful agents, brought to light by toxic dynamics meetings and pharmacodynamics workshops. This emerging field of study is gaining importance in industry with an estimate of more than 7,287 personnel conducting study across the globe. While studying the response and susceptibility parameters like toxic dynamic and pharmacodynamic parameters are taken into consideration to measure the internal exposure and genetic susceptibility to drugs and chemicals.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 8: Biomarkers for Disorders

Biomarkers are the characteristic biological measurable indictors for the various disorders if occurring in abnormal levels. These are used as quantitative entities for neurological disorders, genetic disorders, metabolic disorders, cardiac disorders and inborn errors. The present era is focusing on the cancer research utilizing biomarkers as indictor of disease conditions. The lung cancer biomarkers and biomarkers for breast cancer are inclusive of genes, enzymes, proteins and cell surface entitles. Registering a compound annual growth rate of 14.60% from 2011 to 2018, the market for oncology biomarkers was valued at $13.16 billion in 2011 and is expected to be worth $29.78 billion in 2018.Biomarkers are also used in diagnosing and treating various diseases and disorders like Neurological disorders, Genetic disorders, Metabolic disorders, Cardiac disorders, Inborn errors, Lung cancer and Breast cancer.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 9: Techniques to Maximize Biomarker Identification

Biomarkers are the existing bimolecular and integral indictors of disease condition of biological systems. The techniques used to identify and maximize the expression of biomarkers include RT-PCR genotyping, molecular imaging and dynamics, biochemical  assay and profiling, immunological techniques and chromatographic techniques. A wider approach towards identification of biomarkers lies in the proteomic approach besides utilizing biosensors as a compatible tool for evaluation of biomarker levels in the biological systems. Most of the company’s focus is on generating cost effective durable profiling techniques and equipment to quantify biomarkers within a short span of time. Johnson & Johnson, GlaxoSmithKline Plc., GE Healthcare, Affymetrix Inc., Bio-Rad Laboratories Inc. are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 10: Biomarkers in Nanoscience

Nano science is the study of structures and materials on the scale of nanometres. Nanotechnology may be able to create many new materials and devices with a vast range of applications in medicine, electronics, biomaterials energy production, and consumer products. Nanotechnology is evolving rapidly with nanoparticles events.  An estimated 1 million workers in R&D and production are involved in the field of Nano science and nanomaterial generation. Interaction of biomarkers with nanoparticles aids in identification and validation through biological and biomedical applications. Current market holds Nano devices and nanomaterial for identification, quantifying, calibrating and even in surgeries. The US leads the world in investing and in the number of Nanotech Companies. Global consumption of nanomaterial is expected to grow in unit terms from nearly 225,060 metric tons in 2014 to nearly 584,984 metric tons in 2019, a compound annual growth rate (CAGR) of 21.1% for the period of 2014 to 2019.Nano science is another rapidly growing area where application of nanotechnology to biomarkers is used for biological and biomedical applications like Nano devices.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 11: Biomarkers in Toxicology

Biomarkers are used for detecting kidney toxicity. Kidney toxicity is detected using biomarkers serum creatinine and blood urea nitrogen. Many qualified biomarkers are used to develop products to conquer the kidney toxicity problem. Latest research on biomarkers discovered new approaches to predicting and recognising toxic exposures of macromolecular adducts and their potential consequences.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 12: Biomarkers in Microbial Infections

Biomarkers can be used for microbial infections and can be used for early diagnosis and prognosis of the disease. The diagnostic performance of biomarkers is usually measured in terms of sensitivity.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 13: Biomarkers in Drug Discovery

The role of Biomarkers in drug discovery and development is to understand the pathophysiology of disease. Biomarkers can be a clinical tool for drug discovery and development by confirming the efficacy and safety to the right patient. Biomarkers can be used in understanding the mechanism of drug.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 14: Personalized Medicine and Data Analysis

Recently there has been enhanced and advanced biomedical technology such as high-throughput molecular imaging and microarrays to monitor SNPs, gene and protein expressions, to provide exhaustive situations for individuals. The biological and medical status from such data sets, which are viewed as biomarkers in a wide sense to help to do identification, association, and prediction studies for phenotypes such as cancer subtypes, prognosis, treatment responsiveness, and adverse reactions for personalized medicine.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 15: Nutritional Biomarkers

A nutritional biomarker can be any biological specimen that is an indicator of nutritional status with respect to intake or metabolism of dietary constituents. It can be a biochemical, functional or clinical index of status of an essential nutrient or other dietary constituent. Nutritional biomarkers may be interpreted more broadly as a biologic consequence of dietary intake or dietary patterns.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 16: Current Research Concepts in Biomarkers

Current Research Concepts in Biomarkers include research in glucose disorders, Biomarkers in disease and health, technologies in biomarker discovery, translational biomarker research and the use of biomarkers in pre-clinical and clinical studies.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 17: Oncologists: Biomarkers

An oncologist is a doctor who specializes in treating people with cancer. The oncologist’s research into the causes, prevention, detection, and treatment of cancer is going on in many medical centres throughout the world.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 18: Biomarkers in Market

With the emerging importance to quantify and validate various disease conditions, many organizations, companies, and universities have stepped forward to contribute to the field of biomarkers discovery and quantification for better prognosis of disease conditions. The Biomarkers is the second leading industry after clinical research and development. The Biomarkers in pharmaceutical industry, biomarkers in oncology & other diseases has attained utmost recognition due to global spread of cancer and other diseases. The Biomarkers validation and regulatory affairs and diagnostic biomarker are booming industry with an estimate of more than 270 companies involved across the globe in 2016.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 19: Biomarkers Case Reports

Biomarkers case reports play a crucial role in moving new treatments to patients who need those most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

Track 20: Biomarkers: Entrepreneur Investments Meet

A key ingredient in successful entrepreneurship is self-knowledge. Biomarkers-2016 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from Biomarkers to signalling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts .The speakers will discuss state-of-the-art treatments, current guidelines, clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice. This session will include combined efforts of World-renowned speakers, the most recent techniques, developments, and the newest updates in Biomarkers.

Related Biomarkers Conferences | Cancer Conferences | Biomarkers Meetings

The success of the Biomarkers, Cancer Therapy & Clinical Research has given us the prospect to bring the gathering one more time in Vancouver, Canada during September23-24, 2022. Biomarkers Congress meeting engrossed a vicinity of comprehensive discussions on novel subjects like Biomarkers, Functional Genomics and Cytogenetic Biomarkers, Biomarkers in Clinical Research and Development, Biomarkers for Disorders, Techniques to Maximize Biomarker Identification, Biomarkers in Nano science, Cancer Biomarkers, Functional Transcriptomics and Profiling Techniques, Biomarkers in Toxicology, Biomarkers in Microbial Infections, Biomarkers in Drug Discovery

Biomarkers 2022 extends its warm gratitude to all the previous year’s Honourable Guest and Keynote Speakers of the event:

Biomarkers 2015 | September 01-02, 2015 | Toronto, Canada

• Trevor G Marshall, Autoimmunity Research Foundation, USA
• Claude Prigent, Institute of Genetics and Development of Rennes, France
• Biswendu B Goswami, FDA Center for Food Safety and Applied Nutrition, USA
• Sergey Suchkov, I.M.Sechenov First Moscow State Medical University, Russia
• Alain Moreau, Sainte-Justine University Hospital, Canada
• Chee Gee See, Proteome Sciences, UK
• Martin Weber, Austrian Institute of Technology GmbH, Austria
• Marsha A Moses, Harvard Medical School, USA
• Jan Voskuil, Everest Biotech Ltd., UK
• Scott Marshall, Precision for Medicine, USA

Biomarkers 2016 | December 05-07, 2016 | Philadelphia, Pennsylvania, USA

• Huber Colleen, Naturopathic Oncology Research Institute, USA
• Chen Song, Harvard Medical School, USA
• Ying Mu, Center for Devices and Radiological Health-US FDA, USA
• Al Charest, Beth Israel Deaconess Medical Center Cancer Center, USA
• Jianyu Rao, David Geffen School of Medicine-UCLA, USA
• Andrea Nicolini, University of Pisa, Italy
• Hideshi Ishii, Osaka University Graduate School of Medicine, Japan
• Erik Andrade Jorge, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
• Jose Guadalupe Trujillo Ferrara, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico
• Cheryl McAlpine, Immunocore Ltd., UK

Biomarkers 2017 | October 18-20, 2017 | Baltimore, Maryland, USA

• Frédéric Baribaud, Johnson & Johnson, USA
• David Dongliang Ge, Apostle Inc, USA
• Kamala K Maddali, Cancer Genetics Inc, USA
• Yoshiaki Omura, New York Medical College, USA
• Diana Anderson, University of Bradford, UK
• Srinivas Pentyala, Stony Brook Medical Center, USA
• Jianhua Luo, University of Pittsburgh, USA
• Michael Retsky, Harvard School of Public Health, USA
• David I Smith, Mayo Clinic, USA
• John Michael Sauer, University of Arizona College of Medicine, USA
• Nikolai V Ivanov, Philip Morris International Research & Development, Switzerland
• Lowe Leroy, Lancaster University, UK
• George Vasmatzise, Mayo Clinic, USA
• Sergey Suchkov, I M Sechenov First Moscow State Medical University, Russia
• Qing Kay Li, Johns Hopkins Medical Institutions, USA

Biomarkers 2018 | October 03-04, 2018 | Los Angeles, California, USA

• Michael Retsky, Harvard TH Chan School of Public Health, USA
• Jianhua Luo, University of Pittsburgh School of Medicine, USA
• Li Zhang, The University of Texas at Dallas, USA
• Diana Anderson, University of Bradford, UK
• Magnus S Magnusson, University of Iceland, Iceland
• P Schulz-Knappe, Protagen AG, Germany
• George Vasmatzis, Mayo Clinic, USA
• Huihuang Yan, Mayo Clinic, USA
• Yoshiaki Omura, New York Medical College, USA
• Sushma Umrao, Danal Al Emarat Hospital, UAE
• Bing li, University of Louisville, USA
• Katarína Janšáková, Comenius University, Slovakia

Biomarkers management teams offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with ConferenceSeries Ltd and supported the conference in every aspect.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Biomarkers 2015, Biomarkers 2016, Biomarkers 2017, Biomarkers 2018, Biomarkers 2019. Conference Series LLC Ltd would like to announce the commencement of the “17^th World Congress on Biomarkers, Cancer Therapy & Clinical Research” to be held during September 23-24, 2022 | Vancouver, Canada. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Biomarkers, Cancer Therapy & Clinical Research.

Let us meet again @ Biomarkers 2022

Planning a Trip to Vancouver, Canada!!! Attending Meeting!!!

An issue with VISA!!

Biomarkers 2022 Committee will be happy to help you in all regards to plan your trip to Vancouver, Canada. Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA.

Find out what you need to do to visit Canada as a tourist or business person, how to extend your stay in Canada and what documents you need to carry with you to transit through Canada.

Application submission:

Canada does not have a visa office in every country so it is important that Delegates/Attendees visit the website of the visa office responsible for processing their visa applications.  Information is available on the website on how to submit a visa application and the documentation required. 

Delegates/Attendees are encouraged to submit their visa applications well in advance of the date of the event at a Visa Application Centre or on-line E-applications (e-Apps).

E-Apps

This system allows clients to submit applications online.

Delegates/Attendees that need a visa but require their passport for other travel purposes are strongly encouraged to submit their visa applications online (e-Apps).  Delegates/Attendees that choose to apply online will not have to submit their passport until a decision has been taken on their applications.  If required, the visa office will send the applicant instructions on how and where to send their passports to finalize the visa process.  

Visa Application Centres (VACs):

VACs are commercial service providers authorized by Canada to provide specific services to applicants. 

VACs provide a number of services including help applicants fill out forms, answer questions and ensure that applications are complete, thereby reducing unnecessary delays or refusals due to incomplete applications.

Applicants that are required to provide biometrics information as part of the visa application process can do so at a VAC.  Additional information on the biometrics requirements is available at the IRCC website.

VACs send applications to Visa Offices and transmit decisions to applicants in a secure and confidential manner. VACs do not process visa applications and play no role in the decision-making process.

Visa Applications Processing Time:

Processing time for visa applications vary depending on the office and the time of the year.  Participants should be encouraged to apply early for their visas, and to submit complete applications including all supporting documents.  

Please visit the IRCC website for information on the time it takes to process visa applications at the various visa offices. 

NEW - Electronic Travel Authorization (eTA)

As of March 15, 2016, visa-exempt foreign nationals are expected to have an Electronic Travel Authorization (eTA) to fly to or transit through Canada. Exceptions include U.S. citizens and travelers with a valid Canadian visa. Canadian citizens, including dual citizens, and Canadian permanent residents are not eligible to apply for an eTA.

However, from March 15, 2016, until fall 2016, travellers who do not have an eTA can board their flight, as long as they have appropriate travel documents, such as a valid passport. During this time, border services officers can let travellers arriving without an eTA into the country, as long as they meet the other requirements to enter Canada. We invite you to consult the IRCC website regularly for information updates on eTA.

Best Tourist Destination: Vancouver

• Stanley Park
• Granville Island
• Grouse Mountain
• Museum of Anthropology
• Kitsilano Beach
• Gastown
• Canada Place
• Chinatown
• English Bay
• Capilano Suspension Bridge
• Robson Street
• Museum of Vancouver
• Queen Elizabeth Park
• Science World
• Richmond & Many more…